Table 2.
Changes of TME after treatments with TKIs.
| Mutuation type | Components in TME | Components of TME | Changes after TKIs | Immune activity |
|---|---|---|---|---|
| EGFR | Immune cells | CD8+T | ↑*,#,$ | ↑*,#,$ |
| Effector CD4+ T cells | ↑ | ↑ | ||
| Tregs | ↓*,#,$ | ↑*,#,$ | ||
| B cells | ↑or - | ↑or - | ||
| M1-TAMs | ↑ | ↑ | ||
| M2-TAMs | ↓# | ↑ | ||
| NK cells | ↑# | ↑ | ||
| MDSCs | ↓or suppressive activity ↓ | ↑ | ||
| immunemodulatory molecules | MHC | ↑ | ↑ | |
| PD-L1 | ↓or↑# | ↓or↑# | ||
| CD47 | ↓ | ↑ | ||
| ILT4 | ↓ | ↑ | ||
| cytokines and chemokines | TNF-α, IFN-γ, IL-2 | ↑ | ↑ | |
| IL-6 | ↑ | ↑ | ||
| IL-8 | ↑ | ↑ | ||
| TNF | ↑ | ↑ | ||
| CXCL10 | ↑ | ↑ | ||
| CCL22 | ↓ | ↑ | ||
| CCL2, CCL5 | ↑ | ↓ | ||
| CCL3, CXCL1 | ↓ | |||
| CXCR4 | ↑ | |||
| ALK | Immune cells | CD8+T | activity↓ | ↓ |
| NK cells | ↑ | ↑ | ||
| immunemodulatory molecules | MHC | ↑ | ↑ | |
| PD-L1 | ↑# |
* The change was TKI treatment period dependent.
# The change was TKI sensitivity dependent.
$ The change was TKI treatment regimens dependent.
↑ means up-regulation of the content or the acticity of the relative ingredients in TME.↓ means down-regulation of the content or the acticity of the relative ingredients in TME.